EP1019066B1 - Procedes et compositions pour la prevention et le traitement des brulures d'estomac - Google Patents
Procedes et compositions pour la prevention et le traitement des brulures d'estomac Download PDFInfo
- Publication number
- EP1019066B1 EP1019066B1 EP97945263A EP97945263A EP1019066B1 EP 1019066 B1 EP1019066 B1 EP 1019066B1 EP 97945263 A EP97945263 A EP 97945263A EP 97945263 A EP97945263 A EP 97945263A EP 1019066 B1 EP1019066 B1 EP 1019066B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- heartburn
- famotidine
- antacid
- symptoms
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- Heartburn or pyrosis
- Occasional heartburn is common in normal persons, but frequent and severe heartburn is generally a manifestation of esophageal dysfunction.
- Heartburn may result from abnormal motor activity or distention of the esophagus reflux of acid or bile into the esophagus, or direct esophageal mucosa irritation (esophagitis).
- Heartburn is most often associated with gastroesophageal reflux. In this setting, heartburn typically occurs after a meal, with stooping or bending, or when the patient is supine. It may be accompanied by the spontaneous appearance in the mouth of fluid which may be salty, sour, or bitter and green or yellow. Heartburn may arise following the ingestion of certain foods (e.g. citrus fruit juices) or drugs (e.g. alcohol or aspirin).
- foods e.g. citrus fruit juices
- drugs e.g. alcohol or aspirin
- Reflux esophagitis consists of esophageal mucosal damage resulting from reflux of gastric or intestinal contents into the esophagus.
- Esophagitis an inflammation of the esophagus from regurgitation of acid gastric contents, producing substemal pain, develops when the mucosal defenses that normally counteract the effect of injurious agents on the esophageal mucosa succumb to the onslaught of the refluxed acid pepsin or bile.
- Mild esophagitis shows microscopic changes of mucosal infiltration with granulocytes or eosinophils, hyperplasia of basal cells, and elongation of dermal pegs.
- Erosive esophagitis shows endoscopically visible damage to the mucosa in the form of marked redness, friability, bleeding, superficial linear ulcers, and exudates.
- Known antagonists of the histamine H 2 receptor include cimetidine, ranitidine, nizatidine, and famotidine.
- Famotidine (available from Merck & Co., Inc., Whitehouse Station, NJ, under the name PEPCID ® ), is 3- ⁇ 2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]-N-(aminosulfonyl)propanimidamide, having the structural formula:
- the primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both acid concentration and volume of gastric secretion are reduced by famotidine.
- Famotidine is used to treat acid-related disorders such as gastric and duodenal ulcer, gastroesophageal reflux disease and Zollinger Ellison syndrome. Its safety and efficacy have been well established in controlled clinical studies. It is used by over 31 million patients worldwide.
- Gitlin et al. Amer. Journal of Gastroenterology (1985) vol. 80 pp. 840 examines famotidine efficacy in the treatment of active duodenal ulcers. 20 mg twice daily, 40 mg twice daily and 40 mg at bedtime were administered over a four week period. Healing rates of 67, 75, 70% , respectively, were seen.
- Miyoshi et al. Naika Hokan (1987) vol. 34 pp. 442-457 demonstrates the efficacy of famotidine as a gastritis therapy.
- Miyoshi et al. evaluated dosage regimens of 5, 10, or 20 mg twice daily in the treatment of gastritis symptom relief. Patients treated with 10 to 20 mg of famotidine had fewer erosions and mucosal haemorrhages than those treated with 5 mg famotidine.
- McCallum et al., Dig. Dis. Sci. (1985) vol. 30 pp. 1139-1144 describes a study of healthy patients demonstrating that 5 mg of famotidine produces has an effect on gastric acid secretion.
- Laskin et al ., J. Clin. Pharmacol. (1993) vol. 33 pp. 636-639 describes a study demonstrating that single doses of 5 and 10 mg of famotidine produces statistically significant decreases in intragastric acidity, beginning at 90-100 minutes and persisting for approximately 9 hours.
- H 2 antagonists before ingestion of a heartburn inducing meal may reduce the amount of gastric acid produced and prevent heartburn symptoms.
- H 2 antagonists do not neutralize gastric acid, and the onset of the antisecretory effect of H 2 antagonists is not instantaneous. Therefore, administration of an H 2 antagonist following a meal will not substantially prevent heartburn and related symptoms.
- Antacids are known to neutralize acid in the stomach and may also act locally in the distal esophagus. Antacids are not known to prevent heartburn when taken before food or beverages which may provoke symptoms.
- EP 290 229 describes compositions containing cimetidine, aluminum hydroxide gel, and magnesium hydroxide, for treating duodenal, gastric, recurrent and stomal ulceration, and reflux esophagitis.
- EP 294 933 describes compositions containing cimetidine, aluminum hydroxide gel and magnesium hydroxide, for treating duodenal, gastric, recurrent and stomal ulceration, and reflux esophagitis.
- the antacid is described as providing rapid relief from the symptoms of excess stomach acidity by neutralizing acid and the cimetidine is described as bringing about more sustained relief by inhibiting secretion of acid.
- WO 92/00102 describes coadministration of H 2 antagonists with antacids for treating gastric disorders such as hyperacidity.
- WO 93/12779 describes compositions of H 2 antagonists with antacids for treating gastric disorders such as hyperacidity.
- EP 600 725 describes compositions of famotidine with antacids for treating gastrointestinal distress.
- Applicants have now found that administration to a patient of a composition comprising an H 2 antagonist and antacid, following a heartburn inducing event such as consumption by the patient of heartburn-inducing food or beverage, but prior to development of heartburn, is an effective means for preventing heartburn or reducing the frequency and severity of postprandial heartburn.
- compositions comprising 10 mg famotidine and 21 mEq acid neutralizing capacity of antacid are effective for preventing and treating heartburn symptoms.
- the invention includes a treatment for preventing heartburn episodes in a patient at risk to development of heartburn, comprising administering to the patient, following the heartburn inducing event but prior to development of heartburn, a composition comprising a pharmaceutically effective amount of famotidine and an amount of antacid having 21 mEq acid neutralizing capacity (ANC).
- ANC mEq acid neutralizing capacity
- the invention is also a composition comprising 10 mg famotidine and an amount of antacid of 21 mEq ANC.
- the invention is also a treatment for heartburn symptoms in a patient which comprises administering to the patient an effective amount of a composition comprising 10 mg famotidine and an amount of antacid of 21 mEq ANC.
- the invention includes treatments for preventing, reducing the frequency and severity of, precluding symptoms associated with, and reducing the risk of heartburn episodes in a patient at risk to development of heartburn, comprising administering to the patient, following the heartburn inducing event but prior to development of heartburn, a composition comprising a pharmaceutically effective amount of famotidine and an amount of antacid having 21 mEq ANC.
- These treatments are effective for preventing heartburn related symptoms such as acid indigestion and sour stomach.
- the heartburn inducing event is ingestion of a meal which stimulates gastric acid secretion.
- the H 2 antagonist is famotidine.
- the amount of antacid has 21 ANC.
- the amount of famotidine is 10 mg.
- the invention also includes a treatment for heartburn symptoms in a patient comprising administering to the patient a pharmaceutically effective amount of a composition comprising 10 mg famotidine and an amount of antacid having 21 mEq ANC.
- the invention also includes compositions comprising 10 mg famotidine and an amount of antacid having 21 mEq ANC.
- the composition is in the form of a chewable tablet, the amount of famotidine is 10 mg, and the amount of antacid is 21 mEq ANC.
- compositions of the invention when administered following the heartburn inducing event, show a faster onset of relief than H 2 antagonists alone, and a longer duration of relief than antacid.
- the duration of action of the H 2 antagonist is at least equal to that of a comparable amount of H 2 antagonist administered without antacid.
- preventing heartburn episodes means precluding symptoms, or reducing the severity of symptoms, associated with heartburn in patients susceptible to heartburn following ingestion of heartburn-inducing food or beverage.
- preventding symptoms means making the experience of symptoms impossible or largely ineffectual by removing the conditions needed for them.
- reducing the frequency and severity of postprandial heartburn means substantially lowering the degree of pain associated with heartburn symptoms that would ordinarily occur in patients susceptible to heartburn following ingestion of heartburn-inducing food or beverage.
- reducing the risk of heartburn episodes means substantially lowering the tendency of patients susceptible to heartburn, following ingestion of heartburn-inducing food or beverage, to experience symptoms associated with heartburn following ingestion of heartburn-inducing food or beverage.
- heartburn inducing event includes experience by the patient associated with stimulation of gastric acid secretion and development of heartburn symptoms, such as stress or ingestion of a meal which stimulates gastric acid secretion.
- heartburn-inducing food or beverage includes foods and beverages commonly associated with heartburn in patients susceptible to food- or beverage-induced heartburn episodes, e.g. tomatoes, chili, coffee, red wine, citrus juice, etc.
- meal is hereinafter to be understood to mean heartburn-inducing food and/or beverage.
- the degree of heartburn pain associated with ingestion of such foods varies among individuals and with food types. Thus, some individuals may be more sensitive to certain heartburn-inducing foods than are other individuals.
- the tendency for a given individual to experience heartburn in response to ingestion of a particular food or beverage is predictable, however, and the individual is able to determine, prior to ingestion, which food or beverage will induce heartburn symptoms.
- a "patient susceptible to suffering heartburn episodes following ingestion of heartburn-inducing food or beverage” means any patient who ordinarily experiences symptoms of heartburn caused by ingestion of heartburn-inducing food or beverage.
- the antacids suitable for the present invention are magnesium hydroxide combined with calcium carbonate.
- the H 2 antagonist suitable for the treatments of the invention for preventing heartburn is famotidine.
- a Suitable amount of famotidine is 10 mg.
- compositions of the invention amount of antacid of 21 mEq ANC provide immediate preventative and therapeutic relief necessary for effective prevention and treatment of heartburn symptoms.
- Antacids have known theoretical ANC values (e.g. the ANC of calcium carbonate is 0.020 mEq/mg, and of magnesium hydroxide is 0.0343 mEq/mg - see The United States Pharmacopeia USP 23 NF 18, page 1732 which describes an assay for measuring acid-neutralizing capacity of test substances), and determination of the amount of a specified antacid required to provide a specified ANC can be readily done by persons skilled in the art.
- compositions may also contain pharmaceutically acceptable carriers.
- Compositions are formulated for oral administration in solid form, as chewable tablets. Compositions may thus be formulated by admixture with pharmaceutically acceptable vehicles additionally containing, as desired, pharmaceutically acceptable adjuvants including thickeners, preservatives, coloring agents, flavoring agents and sweeteners, e.g. aspartame, cyclomate and saccharin.
- Powder formulations can be prepared by dry blending ingredients under conditions of controlled temperature and humidity using conventional equipment.
- compositions are in the form of chewable tablets that disintegrate readily in the mouth when chewed.
- Such tablets can be prepared by technology known in the art, including, for example, methods for preparing tablets with barrier layers, such as those described in European Patent Publication 600 725. Such technology is effective for masking the bitter taste associated with H 2 antagonists.
- tablets comprising famotidine and antacid, and amounts of inactive ingredients such as binders, e.g. dextrates and pregelatinized starch, flavors, lubricants e.g. magnesium stearate, colorants, e.g. red ferric oxide, sweetener, e.g. confectioner's sugar, granulating excipient, e.g. lactose hydrous and hydroxy methylcellulose, particle coating such as cellulose acetate and hydroxypropyl cellulose, and wetting agents, e.g. sodium lauryl sulfate sufficient to prepare a pharmaceutically acceptable tablet for delivery of the active famotidine and antacid, were prepared.
- binders e.g. dextrates and pregelatinized starch
- flavors lubricants e.g. magnesium stearate
- colorants e.g. red ferric oxide
- sweetener e.g. confectioner's sugar
- granulating excipient
- a chewable tablet which includes 10 mg famotidine, 800 mg calcium carbonate and 165 mg magnesium hydroxide (which amounts of calcium carbonate and magnesium hydroxide provide 21 mEq ANC) was prepared in the following manner.
- An uncoated famotidine rotorgranulation was prepared by dry blending famotidine with various granulating excipients according to the procedure outlined in European Patent Publication 600 725.
- a rotorgranulated and coated famotidine granulation intermediate was blended with a directly compressible grade of calcium carbonate (DESTAB 95S, available from Particle Dynamics) and a directly compressible magnesium hydroxide powder, dextrates, confectioner's sugar granulation, color, flavors, and then blended. Magnesium stearate was then added to the blender to form the final blend. The lubricated mixture was compressed into single-layer, round pale rose colored tablets on appropriate tooling.
- DESTAB 95S directly compressible grade of calcium carbonate
- Example 1 The procedure of Example 1 is followed, using 330 mg magnesium hydroxide and 1600 mg calcium carbonate, to provide a famotidine/antacid chewable tablet having 42 ANC.
- a non-chewable tablet having the following composition is prepared: Ingredient mg Famotidine 10.0 Magnesium hydroxide 165.0 Calcium carbonate 800.0 Magnesium stearate 5.0 Pregelatinized starch 40.0 Carboxymethylcellulose 100.0
- Famotidine, magnesium hydroxide, calcium carbonate, carboxymethylcellulose, and a portion of the starch are mixed and granulated.
- the resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate.
- the resulting granulation is then compressed into tablets.
- a non-chewable tablet having the following composition is prepared: Ingredient mg Coated famotidine granulation 86.4 Magnesium hydroxide 165.0 Calcium carbonate 800.0 Magnesium stearate 5.0 Pregelatinized starch 40.0 Carboxymethylcellulose 100.0
- Coated famotidine granulation (used in Example 1), magnesium hydroxide, calcium carbonate, carboxymethylcellulose, and a portion of the starch are mixed and granulated. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets.
- a non-chewable tablet having the following composition is prepared: Ingredient mg Famotidine 10.0 Magnesium hydroxide 330.0 Calcium carbonate 1600.0 Magnesium stearate 5.0 Pregelatinized starch 40.0 Carboxymethylcellulose 100.0
- Famotidine, magnesium hydroxide, calcium carbonate, carboxymethylcellulose, and a portion of the starch are mixed and granulated.
- the resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate.
- the resulting granulation is then compressed into tablets.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (1)
- Composition pharmaceutique à mâcher monocouche comprenant 10 mg de famotidine, 800 mg de carbonate de calcium et 165 mg d'hydroxyde de magnésium, dans laquelle la famotidine a été granulée dans un rotor et enrobée.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2765996P | 1996-10-04 | 1996-10-04 | |
US27659P | 1996-10-04 | ||
GBGB9624291.2A GB9624291D0 (en) | 1996-11-22 | 1996-11-22 | Methods and compositions for preventions and treating heartburn |
GB9624291 | 1996-11-22 | ||
PCT/US1997/017083 WO1998014198A1 (fr) | 1996-10-04 | 1997-09-30 | Procedes et compositions pour la prevention et le traitement des brulures d'estomac |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1019066A4 EP1019066A4 (fr) | 2000-07-19 |
EP1019066A1 EP1019066A1 (fr) | 2000-07-19 |
EP1019066B1 true EP1019066B1 (fr) | 2006-11-15 |
Family
ID=26310458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97945263A Expired - Lifetime EP1019066B1 (fr) | 1996-10-04 | 1997-09-30 | Procedes et compositions pour la prevention et le traitement des brulures d'estomac |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1019066B1 (fr) |
JP (1) | JP2001501224A (fr) |
AT (1) | ATE345138T1 (fr) |
AU (1) | AU728423B2 (fr) |
CA (1) | CA2267503C (fr) |
DE (1) | DE69736955T2 (fr) |
DK (1) | DK1019066T3 (fr) |
ES (1) | ES2274550T3 (fr) |
WO (1) | WO1998014198A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080248136A1 (en) * | 2006-10-25 | 2008-10-09 | Iomedix Development International Srl | Acute and chronic heartburn composition and method |
WO2017091166A1 (fr) | 2015-11-26 | 2017-06-01 | Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. | Compositions pharmaceutiques stables et leur procédé de préparation |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1363399A (en) * | 1972-04-13 | 1974-08-14 | Rotta Research Lab | Method of preparing an antacid pharmaceutical product |
US4163777A (en) * | 1977-04-29 | 1979-08-07 | Lewis/Howe Company | Controlled antacid delivery form and method of treatment therewith |
US4486412A (en) * | 1983-03-15 | 1984-12-04 | Pharmacaps, Inc. | Encapsulated antacid dispersions |
CA1239349A (fr) * | 1983-10-10 | 1988-07-19 | Eberhard F. Gottwald | Compose pharmaceutique contenant de la cimetidine |
JPH0764737B2 (ja) * | 1984-04-19 | 1995-07-12 | ローヌ−プーラン ローラー インターナショナル (ホウルディングス) インコーポレイテッド | 制酸組成物 |
IE58636B1 (en) * | 1984-10-17 | 1993-10-20 | American Home Prod | Fluidized and rehydratable magaldrate compositions |
US4744986A (en) * | 1986-03-07 | 1988-05-17 | Rorer Pharmaceutical Corporation | Process for the preparation of a viscosity-stable antacid composition |
KR960011236B1 (ko) * | 1987-05-08 | 1996-08-21 | 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 | 제약학적 조성물 및 고체 제형 |
ATE73328T1 (de) * | 1987-05-08 | 1992-03-15 | Smith Kline French Lab | Pharmazeutische zusammensetzungen. |
US4988679A (en) * | 1989-01-03 | 1991-01-29 | Leonard Chavkin | Liquid sustained release composition |
US5299137A (en) * | 1990-04-05 | 1994-03-29 | Vlsi Technology, Inc. | Behavioral synthesis of circuits including high impedance buffers |
CA2085873A1 (fr) * | 1990-06-22 | 1991-12-23 | Adrian Francis Davis | Traitement |
CA2055661A1 (fr) * | 1990-12-21 | 1992-06-22 | Manley A. Paulos | Traitement des maux d'estomac associes aux brulures d'estomac ou a une hyperacidite gastrique au moyen d'une formulationeffervescente bloquant h2 |
GB9127150D0 (en) * | 1991-12-20 | 1992-02-19 | Smithkline Beecham Plc | Novel treatment |
US5229137A (en) * | 1992-05-06 | 1993-07-20 | Brigham And Women's Hospital, Inc. | Methods and pharmaceutical compositions for treating episodic heartburn |
CA2110313C (fr) * | 1992-12-01 | 2004-10-26 | Edward John Roche | Compositions pharmaceutiques contenant un compose de guanidothiazole et antiacides |
WO1995001792A1 (fr) * | 1993-07-06 | 1995-01-19 | Merck & Co., Inc. | Composes anti-h2-antihistaminiques |
CA2166731A1 (fr) * | 1993-07-06 | 1995-01-19 | Robert T. Sims | Combinaisons d'antacide, d'alginate et d'antagoniste des recepteurs de h2 |
IT1264546B1 (it) * | 1993-07-30 | 1996-10-02 | Lisapharma Spa | Composizione farmaceutica ad attivita' antiacida in forma di sospensione a base di gel di sucralfato |
US5667794A (en) * | 1995-05-02 | 1997-09-16 | Merck & Co., Inc. | Heartburn treatment |
-
1997
- 1997-09-30 ES ES97945263T patent/ES2274550T3/es not_active Expired - Lifetime
- 1997-09-30 AT AT97945263T patent/ATE345138T1/de active
- 1997-09-30 WO PCT/US1997/017083 patent/WO1998014198A1/fr active IP Right Grant
- 1997-09-30 AU AU46506/97A patent/AU728423B2/en not_active Expired
- 1997-09-30 DE DE69736955T patent/DE69736955T2/de not_active Expired - Lifetime
- 1997-09-30 CA CA002267503A patent/CA2267503C/fr not_active Expired - Lifetime
- 1997-09-30 EP EP97945263A patent/EP1019066B1/fr not_active Expired - Lifetime
- 1997-09-30 JP JP10516635A patent/JP2001501224A/ja active Pending
- 1997-09-30 DK DK97945263T patent/DK1019066T3/da active
Also Published As
Publication number | Publication date |
---|---|
DE69736955T2 (de) | 2007-07-12 |
DE69736955D1 (de) | 2006-12-28 |
CA2267503A1 (fr) | 1998-04-09 |
AU4650697A (en) | 1998-04-24 |
AU728423B2 (en) | 2001-01-11 |
CA2267503C (fr) | 2002-04-30 |
ATE345138T1 (de) | 2006-12-15 |
EP1019066A4 (fr) | 2000-07-19 |
EP1019066A1 (fr) | 2000-07-19 |
JP2001501224A (ja) | 2001-01-30 |
DK1019066T3 (da) | 2007-02-26 |
WO1998014198A1 (fr) | 1998-04-09 |
ES2274550T3 (es) | 2007-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5989588A (en) | Methods and compositions for preventing and treating heartburn | |
US5854267A (en) | Method for preventing heartburn | |
US5229137A (en) | Methods and pharmaceutical compositions for treating episodic heartburn | |
TWI402074B (zh) | 藉由特定多糖類來降低胃灼熱及胃食道逆流疾病(gerd)之症狀的方法 | |
US7776831B2 (en) | Use of antifungal compositions to treat upper gastrointestinal conditions | |
US4689229A (en) | Gastrointestinal compositions | |
McQuaid et al. | Medical therapy of peptic ulcer disease | |
EP1019066B1 (fr) | Procedes et compositions pour la prevention et le traitement des brulures d'estomac | |
US20180140630A1 (en) | Combination of an h2-receptor antagonist, antacid, and alginic acid to treat episodic heartburn | |
US6537525B1 (en) | Medicated chewing-gum | |
US5667794A (en) | Heartburn treatment | |
CA2178277C (fr) | Methode pour prevenir les brulures d'estomac | |
WO1995016446A1 (fr) | Composes a base de ranitidine | |
JP2000219625A (ja) | 医薬組成物 | |
PT1019066E (pt) | Métodos e composições para a prevenção e tratamento da azia | |
WO1996008238A1 (fr) | Utilisation d'agents d'accroissement paracellulaires tels que le glucose pour accroitre l'absorption d'antagonistes du recepteur h2 de l'histamine | |
JP2007091761A (ja) | H.pyloriに起因する胃腸障害の処置のためのスピラマイシン含有薬剤 | |
AU677108B2 (en) | Ranitidine and calcium carbonate pharmaceutical combination product | |
AU690664B2 (en) | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion | |
WO1996002262A2 (fr) | Compositions pharmaceutiques pour le traitement de douleurs gastriques, comprenant des antiacides et des antagonistes des recepteurs h2 a l'histamine | |
MXPA96004553A (en) | Compositions of dosing ranitidine b | |
WO1997040843A2 (fr) | Methode de prevention de troubles gastro-intestinaux | |
MXPA96004986A (es) | Utilizacion de espiramicina en transtornos gastrointestinales causados por h. pylori |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990504 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19991126 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20010608 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MCNEIL-PPC, INC. Owner name: MERCK & CO., INC. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/425 20060101ALI20060322BHEP Ipc: A61K 33/08 20060101ALI20060322BHEP Ipc: A61K 45/06 20060101ALI20060322BHEP Ipc: A61K 33/10 20060101ALI20060322BHEP Ipc: A61K 33/00 20060101AFI20060322BHEP |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69736955 Country of ref document: DE Date of ref document: 20061228 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20061227 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO.AG PATETN- UND MARKENANWAELTE Ref country code: GR Ref legal event code: EP Ref document number: 20070400130 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2274550 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20070817 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: MCNEIL-PPC, INC. Free format text: MERCK & CO., INC.#126 EAST LINCOLN AVENUE#RAHWAY, NEW JERSEY 07065 (US) $ MCNEIL-PPC, INC.#GRANDVIEW ROAD#SKILLMAN, NEW JERSEY 08558 (US) -TRANSFER TO- MCNEIL-PPC, INC.#GRANDVIEW ROAD#SKILLMAN, NEW JERSEY 08558 (US) $ MERCK SHARP & DOHME CORP.#126 EAST LINCOLN AVENUE#RAHWAY, NJ 07065 (US) |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD Ref country code: FR Ref legal event code: CA |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: "MERCK SHARP & Effective date: 20110805 Ref country code: ES Ref legal event code: PC2A Owner name: MERCK SHARP & DOHME CORP. Effective date: 20110805 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFUS Owner name: SCHERING CORPORATION, US Free format text: FORMER OWNER: MCNEIL-PPC, INC., US Ref country code: CH Ref legal event code: PFA Owner name: MCNEIL-PPC, INC. Free format text: MCNEIL-PPC, INC.#GRANDVIEW ROAD#SKILLMAN, NEW JERSEY 08558 (US) $ SCHERING CORPORATION#2000 GALLOPING HILL ROAD#KENILWORTH, NJ 07033 (US) -TRANSFER TO- MCNEIL-PPC, INC.#GRANDVIEW ROAD#SKILLMAN, NEW JERSEY 08558 (US) $ MERCK SHARP & DOHME CORP.#126 EAST LINCOLN AVENUE#RAHWAY, NEW JERSEY 07065 (US) |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Owner name: SCHERING CORPORATION, US Effective date: 20120711 |
|
BECA | Be: change of holder's address |
Owner name: MERCK SHARP & DOHME CORP. Effective date: 20120802 Owner name: GRANDVIEW ROAD,SKILLMAN NEW JERSEY 08558(US) Effective date: 20120802 Owner name: 126 EAST LINCOLN AVENUE, RAHWAY NEW JERSEY 07065 Effective date: 20120802 Owner name: MCNEIL-PPC, INC. Effective date: 20120802 |
|
BECH | Be: change of holder |
Owner name: MERCK SHARP & DOHME CORP. Effective date: 20120802 Owner name: MCNEIL-PPC, INC. Effective date: 20120802 |
|
BECN | Be: change of holder's name |
Owner name: MCNEIL-PPC, INC. Effective date: 20120802 Owner name: MERCK SHARP & DOHME CORP. Effective date: 20120802 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: TD Effective date: 20120828 Ref country code: NL Ref legal event code: SD Effective date: 20120828 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: TD Effective date: 20120924 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: MERCK SHARP & DOHME CORP Effective date: 20121024 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TQ Owner name: MCNEIL-PPC, INC, US Effective date: 20130318 Ref country code: FR Ref legal event code: TQ Owner name: SCHERING CORPORATION, US Effective date: 20130318 Ref country code: FR Ref legal event code: CD Owner name: MCNEIL-PPC, INC, US Effective date: 20130319 Ref country code: FR Ref legal event code: CD Owner name: SCHERING CORPORATION, US Effective date: 20130319 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: PC Ref document number: 345138 Country of ref document: AT Kind code of ref document: T Owner name: MERCK SHARP & DOHME CORP., US Effective date: 20130508 Ref country code: AT Ref legal event code: PC Ref document number: 345138 Country of ref document: AT Kind code of ref document: T Owner name: MCNEIL-PPC, INC., US Effective date: 20130508 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 69736955 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 69736955 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 69736955 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20130704 AND 20130710 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 69736955 Country of ref document: DE Representative=s name: ABITZ & PARTNER PATENTANWAELTE MBB, DE Effective date: 20130618 Ref country code: DE Ref legal event code: R082 Ref document number: 69736955 Country of ref document: DE Representative=s name: ABITZ & PARTNER PATENTANWAELTE MBB, DE Effective date: 20130625 Ref country code: DE Ref legal event code: R082 Ref document number: 69736955 Country of ref document: DE Representative=s name: ABITZ & PARTNER PATENTANWAELTE MBB, DE Effective date: 20130626 Ref country code: DE Ref legal event code: R082 Ref document number: 69736955 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE Effective date: 20130618 Ref country code: DE Ref legal event code: R082 Ref document number: 69736955 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE Effective date: 20130625 Ref country code: DE Ref legal event code: R082 Ref document number: 69736955 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE Effective date: 20130626 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US Free format text: FORMER OWNERS: MERCK & CO., INC., 07065 RAHWAY, N.J., US; MCNEILL-PPC, INC., SKILLMAN, N.J., US Effective date: 20130618 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MCNEILL-PPC, INC., SKILLMAN, US Free format text: FORMER OWNERS: MCNEILL-PPC, INC., SKILLMAN, N.J., US; MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, NEW JERSEY, US Effective date: 20130625 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US Free format text: FORMER OWNERS: MCNEILL-PPC, INC., SKILLMAN, N.J., US; MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, NEW JERSEY, US Effective date: 20130625 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MCNEILL-PPC, INC., SKILLMAN, US Free format text: FORMER OWNERS: MCNEILL-PPC, INC., SKILLMAN, N.J., US; SCHERING CORPORATION, RAHWAY, US Effective date: 20130626 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MCNEILL-PPC, INC., SKILLMAN, US Free format text: FORMER OWNERS: MERCK & CO., INC., 07065 RAHWAY, N.J., US; MCNEILL-PPC, INC., SKILLMAN, N.J., US Effective date: 20130618 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US Free format text: FORMER OWNERS: MCNEILL-PPC, INC., SKILLMAN, N.J., US; SCHERING CORPORATION, RAHWAY, US Effective date: 20130626 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US Free format text: FORMER OWNER: MCNEILL-PPC, INC., SCHERING CORPORATION, , US Effective date: 20130626 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US Free format text: FORMER OWNER: MCNEILL-PPC, INC., MERCK SHARP & DOHME CORP., , US Effective date: 20130625 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US Free format text: FORMER OWNER: MERCK & CO., INC., MCNEILL-PPC, INC., , US Effective date: 20130618 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MCNEILL-PPC, INC., SKILLMAN, US Free format text: FORMER OWNER: MCNEILL-PPC, INC., MERCK SHARP & DOHME CORP., , US Effective date: 20130625 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MCNEILL-PPC, INC., SKILLMAN, US Free format text: FORMER OWNER: MERCK & CO., INC., MCNEILL-PPC, INC., , US Effective date: 20130618 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MCNEILL-PPC, INC., SKILLMAN, US Free format text: FORMER OWNER: MCNEILL-PPC, INC., SCHERING CORPORATION, , US Effective date: 20130626 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., US Free format text: FORMER OWNER: MERCK & CO., INC., MCNEILL-PPC, INC., , US Effective date: 20130618 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MCNEILL-PPC, INC., US Free format text: FORMER OWNER: MCNEILL-PPC, INC., MERCK SHARP & DOHME CORP., , US Effective date: 20130625 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., US Free format text: FORMER OWNER: MCNEILL-PPC, INC., MERCK SHARP & DOHME CORP., , US Effective date: 20130625 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., US Free format text: FORMER OWNER: MCNEILL-PPC, INC., SCHERING CORPORATION, , US Effective date: 20130626 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MCNEILL-PPC, INC., US Free format text: FORMER OWNER: MCNEILL-PPC, INC., SCHERING CORPORATION, , US Effective date: 20130626 Ref country code: DE Ref legal event code: R081 Ref document number: 69736955 Country of ref document: DE Owner name: MCNEILL-PPC, INC., US Free format text: FORMER OWNER: MERCK & CO., INC., MCNEILL-PPC, INC., , US Effective date: 20130618 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20160914 Year of fee payment: 20 Ref country code: IE Payment date: 20160909 Year of fee payment: 20 Ref country code: GB Payment date: 20160928 Year of fee payment: 20 Ref country code: IT Payment date: 20160921 Year of fee payment: 20 Ref country code: FI Payment date: 20160909 Year of fee payment: 20 Ref country code: LU Payment date: 20160920 Year of fee payment: 20 Ref country code: DK Payment date: 20160912 Year of fee payment: 20 Ref country code: NL Payment date: 20160913 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20160914 Year of fee payment: 20 Ref country code: PT Payment date: 20160916 Year of fee payment: 20 Ref country code: GR Payment date: 20160812 Year of fee payment: 20 Ref country code: FR Payment date: 20160816 Year of fee payment: 20 Ref country code: AT Payment date: 20160826 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20160811 Year of fee payment: 20 Ref country code: BE Payment date: 20160815 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20160927 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69736955 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Effective date: 20170930 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20170929 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20170929 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 345138 Country of ref document: AT Kind code of ref document: T Effective date: 20170930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20170929 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MK Effective date: 20170930 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20180126 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20170930 Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20171010 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20171001 |